Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer paying out millions, again, to settle off-label promotion charges in the US

This article was originally published in SRA

Executive Summary

Once again, US pharma giant Pfizer is having to pay out millions of dollars to the US federal government and states to settle charges of illegal promotion of the company's medicines, with the latest settlements totaling about $98 million1. While a far cry from the $2.3 billion the New York drug maker paid under a 2009 guilty plea for promoting its cyclooxygenase-2-selective nonsteroidal anti-inflammatory drug Bextra (valdecoxib), this is still a tidy sum of cash2.

You may also be interested in...



Unintended Consequences Of Broad Opioid-Sparing Claims Worries US Panel

FDA advisory committee members raise concerns about inappropriate marketing and prescribing practices. 

US FDA Learns 'Lessons Of History,' Takes Opioid Fight To Gabapentinoids

Agency investigating potential misuse and abuse of gabapentinoids, which CDC had recommended as alternative to opioids, in latest twist to epidemic.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel